KRAS and cancer: Herein, we describe the biological and preclinical characterization of IAG933 and its close analogs, their monotherapy activity in specific Hippo-dependent cancers and in combination with receptor tyrosine kinases (RTKs), KRAS, BRAF, MEK or ERK inhibitors in a broad range of other cancer models.